Catalent Introduces New Web Tool To Solve Formulation Challenges - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent Introduces New Web Tool To Solve Formulation Challenges
New interactive web tool helps innovators match formulations to drug delivery technologies.


Catalent Pharma Solutions announced that it will launch a new ‘FormProRx’ web tool on Nov. 11, during the 2013 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition. The web-based scientific resource has been developed to assist drug development teams seeking to determine the optimal finished dose suited to their product based on product requirements, target indications and molecule properties.

FormProRx enables users to evaluate multiple oral drug delivery technologies and establish which is most appropriate for their compound. Users can gain access to a customized report for their API characteristics and product requirements across 24 dimensions under the categories ‘solubility & permeability,’ ‘physiochemical properties,’ ‘potent handling’ and ‘API processing.’ On completing the profile, the user then receives a detailed report on which drug delivery technologies could be appropriate for further investigation. Whether for a new drug or a line extension, insights from FormProRx may suggest new approaches that benefit pharmacokinetics, patient adherence or the formulation’s therapeutic profile.

"It is ever more challenging to deliver drugs effectively in a form that is convenient for patients and minimizes side effects. Formulators can drive better outcomes through familiarity with the many drug delivery technologies available," commented Dr. Kurt Nielsen, chief technology officer and senior vice president of innovation and growth at Catalent, in a press statement. “By introducing a tool that suggests drug delivery technologies based on the specific characteristics of the molecule, and yet is fast and easy-to-use, Catalent aims to help innovators improve their treatments and advance them faster. It is built on the knowledge of many scientists with broad experience developing hundreds of molecules and provides an excellent aid to development teams.”

Source: Catalent

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here